ResearcherXijing HospitalNo recent work listed

Cheng Fang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8042-0643; OpenAlex author ID A5007223219. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper

Papers 2

Dysbindin promotes progression of pancreatic ductal adenocarcinoma via direct activation of PI3K. Co-author DOI 10.1093/jmcb/mjx043 ↗
Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling. Co-author DOI 10.1002/ijc.30227 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xin Guo · 2 shared papers, 2016–2017 · strength 0.12
- Paper Dysbindin promotes progression of pancreatic ductal adenocarcinoma via direct activation of PI3K. DOI 10.1093/jmcb/mjx043 ↗
- Paper Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling. DOI 10.1002/ijc.30227 ↗
Yong Chen · 2 shared papers, 2016–2017 · strength 0.12
- Paper Dysbindin promotes progression of pancreatic ductal adenocarcinoma via direct activation of PI3K. DOI 10.1093/jmcb/mjx043 ↗
- Paper Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling. DOI 10.1002/ijc.30227 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.